Technology | April 09, 2026
Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The new capital is expected to fund the company through 2029
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
He brings extensive cross-functional expertise built through leadership roles
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
Subscribe To Our Newsletter & Stay Updated
